An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

The ongoing Ebola virus disease epidemic in the Democratic Republic of Congo (DRC) is moving faster than any previous outbreak, said WHO chief Dr Tedros Adhanom Ghebreyesus.

According to official data, confirmed cases have reached 4,449, with the death toll climbing to 2,061 across five provinces and 53 health zones in the country. However, the number of uncounted cases may be far higher than the reported figure.

“It is already the second-biggest Ebola epidemic on record, and it is moving faster than any previous Ebola outbreak. At its current pace, it is on track to eclipse the West African Ebola outbreak of 2014 to 2016,” Tedros said in a briefing.

The 2014-2016 outbreak reported at least 28,000 cases and took about eight months to reach 1,000 deaths.

Ebola 2026: Big Head Start, Likely to Peak in 6 Months

Tedros noted that the current “outbreak had a big head start, it is still way ahead of us, and we are playing catch-up.”

He said this even as reports showed that the disease caused by the rare Bundibugyo virus had been circulating since February and went undetected for months. The WHO declared the outbreak on May 15.

Dr Abdirahman Mahamud, WHO’s director for health emergency alert and response operations, said the agency expects the outbreak to reach its peak within six months, AP News reported.

“But ... that’s the moderate scenario,” Mahamud said. “There is a one-case scenario where this outbreak may last nine months to 12 months.”

Unknown Chains of Transmission

Tedros said about 90% of all cases and 80% of deaths are in the province of Ituri, with sustained transmission in the towns of Bunia, Rwampara, Nizi and Lita.

“Most concerningly, we see a high proportion of deaths in communities instead of treatment units, outside of known contact lists,” Tedros said.

“That tells us there are chains of transmission we don’t know about, and until we know about – and break – every chain of transmission, we will not stop the outbreak.”

Most transmission happens when people have late-stage disease and are not in treatment, or when their bodies are handled after death.

Early clinical care and safe and dignified burials are therefore critical for interrupting transmission. Both depend on the trust of affected communities, making community engagement and ownership essential.

“There is no other way,” Tedros said, adding that the response is now being scaled up, with the primary goal of interrupting transmission.

With partners, WHO is mapping and pooling resources to strengthen community-based surveillance, bring every suspected case into care and reach the 95% contact-tracing target needed to interrupt transmission. Currently, the rate is around 80%.

Progress Made

• More than 21,000 community health workers have been trained.
• Treatment centres, safe burial teams, laboratories and community engagement teams are operating across the affected provinces, reaching hundreds of thousands of people.
• A total of 886 patients have recovered, even without specific therapeutics and vaccines, which are progressing through trials.
• For the first time, two vaccines specifically designed against Bundibugyo virus have entered Phase 1 safety trials in humans.
• Two new animal studies of a vaccine against Zaire ebolavirus — the more common species — have shown promising evidence of cross-protection in animals, Tedros said.

American drugmaker Eli Lilly has sued six companies in the US over the alleged illegal sale of its experimental weight-loss drug retatrutide.

In a statement, Lilly said that the lawsuits target US entities allegedly selling illegal retatrutide products, claiming that their products are for “research use only” while allegedly marketing them for human use. These include

• compounding pharmacies,
• medical spas
• online sellers.

“Retatrutide is being rigorously studied as part of a comprehensive clinical trial development program,” said David A. Hyman, Lilly’s chief medical officer.

“We take the responsibility of evaluating the safety and efficacy of our investigational medicines seriously. What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk,” he added.

Which Six Companies Is Lilly Suing?

Lilly has filed lawsuits against:

• Aesthetic Envy Cosmetic Centers LLC, doing business as Aesthetic Envy
• Astra LLC, doing business as Astra Peptides
• Legendary Peptides, LLC
• Striker Pharmacy, LLC
• Texas Peptides Inc
• Lone Star Peptide Co

Black-Market Retatrutide

Lilly said it has referred more than 200 individuals and entities to the US Food and Drug Administration (FDA), the US Department of Justice, state attorneys general, law enforcement agencies and professional licensing boards.

The company is also working with regulators, law enforcement and customs authorities worldwide to address the illegal market.

Lilly urged social media and e-commerce platforms, credit card companies, payment processors, and shipping and logistics companies used by sellers to help protect patients and tackle the illicit activity.

The drugmaker noted that it has reported more than 14,000 websites, advertisements, social media posts and product listings that allegedly market retatrutide unlawfully across more than 100 countries to internet service providers, social media platforms and e-commerce companies.

FDA Says Unapproved Retatrutide Is Illegal

The US FDA has made clear that selling unapproved retatrutide directly to consumers is illegal. Retatrutide also cannot be lawfully compounded.

The FDA has warned that so-called “research-use only” products are of unknown quality and may pose risks to consumers’ health.

Black-market sellers and businesses posing as legitimate medical providers have openly marketed retatrutide as a weight-loss “hack.”

According to Lilly, such products are frequently made by unregulated foreign manufacturers. Regulators, customs agencies and law enforcement authorities worldwide have warned about these products and have taken actions including raiding clandestine manufacturing sites, seizing shipments and making arrests.

What Is Retatrutide?

Retatrutide is one of Eli Lilly’s next-generation obesity treatments and is currently under development. Unlike Lilly’s currently approved GLP-1 drugs, retatrutide activates three hormone receptors: GLP-1, GIP and glucagon.

Researchers believe this triple-action approach could help people lose excess weight by reducing appetite while also increasing energy expenditure.

Retatrutide Shows Promise in Trials

Retatrutide has attracted significant interest after late-stage clinical trials showed some of the highest weight-loss outcomes reported with an obesity medication. In Phase 3 studies, adults without diabetes who received the highest dose lost more than 28% of their body weight over 80 weeks.

Lilly plans to submit retatrutide for approval to the US FDA in the first quarter of 2027.

President Donald Trump on Monday signed an executive order calling for fewer routine childhood vaccinations and directing the Justice Department to challenge state vaccine laws, a move swiftly rejected by physicians and vaccine makers.

The order, signed on August 10, calls for childhood vaccines to be administered at separate medical visits whenever possible and narrows federal recommendations to vaccines against 11 core diseases.

"For too long, America recommended more childhood vaccines than any peer nation. No longer," the White House share in a post on X.

It also directs federal health agencies to develop a plan for separate measles, mumps and rubella vaccines, which are currently not available as individual shots in the US.

What Does the Executive Order Say?

The executive order, titled “Delivering Gold Standard Childhood Vaccine Recommendations for Americans,” cuts the number of vaccines recommended for all children from 18 to 11.

• Immunizations recommended for all children: Measles, mumps, rubella, diphtheria, tetanus, pertussis (whooping cough), polio, Haemophilus influenzae type B (Hib), pneumococcal disease, human papillomavirus (HPV), and varicella (chickenpox).

• Immunizations recommended for certain high-risk groups or populations: Respiratory syncytial virus (RSV) monoclonal antibodies, hepatitis A, hepatitis B, meningococcal B, meningococcal ACWY, and dengue for children with certain underlying conditions or specific exposure risks.

• Immunizations based on shared clinical decision-making: Hepatitis A, hepatitis B, rotavirus, meningococcal disease, influenza, and COVID-19 are to be considered in consultation with a doctor based on the child’s individual circumstances.

Splitting the MMR Vaccine

Also read: Donald Trump Signs Order To Split MMR Vaccine: Is It Safe For Children?

The order calls for the combined MMR vaccine to be replaced by separate measles, mumps, and rubella shots.

The MMR vaccine currently protects children against all three diseases with a combination shot. Under existing CDC guidance, children receive two doses, generally at 12 to 15 months and again at 4 to 6 years.

Trump claimed that “there could be a possibility” the MMR vaccine is “quite lethal,” but said that when separated, the vaccines are “not at all lethal, but just very effective.”

Trump also suggested that vaccines cause autism, despite a lack of scientific evidence showing a link.

The CDC and many major medical groups have long recommended the combined vaccine because it reduces the number of injections and lowers the risk that children will miss protection against one of the three diseases.

When Will the Order Be Implemented?

The new executive order does not immediately replace the current CDC childhood immunization schedule. It, instead, directs the HHS Task Force on Safer Childhood Vaccines to develop plans within 90 days to assess vaccine timing and sequencing and adjust the federal schedule as appropriate and consistent with applicable law.

There are also logistical hurdles. Individual measles, mumps and rubella vaccines are not currently licensed in the US. The combined MMR vaccine is manufactured by Merck and GSK for the US market. Merck stopped making single-disease shots for measles, mumps and rubella in 2008, and such vaccines are not routinely used in most other countries.

Merck and GSK said there is no published scientific evidence supporting separation of the vaccines and that decades of evidence support the safety of the combined MMR vaccine.

“Even under current expedited review pathways, it could take years — potentially as many as 10 — to meet the safety and efficacy requirements to obtain FDA approval and then begin manufacturing and commercialization” of single-disease shots, Merck said.

Dr. Andrew Racine, president of the American Academy of Pediatrics, said that although it is possible to separate the MMR vaccine into its individual components, each component would need to be manufactured and tested.

“They wouldn't be able to do that probably for another 10 years, and there's no indication that they have any interest in doing that,” Racine was quoted by Reuters as saying.

Read More: Amid Cyclospora, Salmonella Outbreaks, US FDA Issues Guidance on Ready-to-Eat Produce

WHO expresses Concern

Taking to social media platform X, WHO Director-General Dr. Tedros Adhanom Ghebreyesus said that “vaccines are among the most powerful tools” for keeping children safe and “making deadly diseases preventable.”

Expressing concern about the changes to US immunization policy, the WHO said they “are not aligned with decades of evidence that show when children are most vulnerable to disease, when vaccines provide the strongest protection, how many doses are needed, and which vaccines can be given together safely.”

“The current evidence is unequivocal: vaccines — including the MMR vaccine — are safe and do not cause autism,” he said, adding that “delaying vaccines or separating doses unnecessarily does not make vaccination safer and can leave children unprotected.”

Dr. Andrew Racine, president of the American Academy of Pediatrics, said the announcement could create unnecessary uncertainty for families.

“Science about vaccines and their efficacy has not changed,” Racine said.